Dr. Takehito Okui studied molecular physiology and hematology, especially he focused on the hepatic erythropoiesis in African clawed frogs (Xenopus laevis) during graduate course. Through those studies, he received his doctorate, Doctor of Science (D.Sc.), in Department of Integrative Bioscience and Biomedical Engineering at Waseda University. After graduation, he joined to Kowa Company, Ltd., and began studying dyslipidemia in Pharmacology Department at Tokyo New Drug Research Laboratories from 2013. In February 2017, he joined to Dr. Elena Aikawa’s group at Center for Interdisciplinary Cardiovascular Sciences (CICS), and has been researching to clarify the mechanisms and to identify new therapeutic target for cardiovascular calcification.